Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
MWN-AI** Summary
Prothena Corporation plc (NASDAQ: PRTA) announced that its partner, Bristol Myers Squibb (BMS), has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BMS-986446, also known as PRX005. This monoclonal antibody, part of a Phase 2 clinical trial, targets the anti-microtubule binding region of tau (anti-MTBR-tau) and is being investigated as a disease-modifying therapy for early Alzheimer's disease. The Fast Track designation aims to facilitate the development and review of drugs for conditions that address unmet medical needs, highlighting BMS-986446's potential impact on Alzheimer's treatment.
Alzheimer's disease, the most prevalent form of dementia, is a devastating neurodegenerative condition characterized by the accumulation of pathological tau protein that disrupts neuronal communication and leads to cognitive decline. BMS-986446 seeks to neutralize the spread of this harmful tau protein and promote its clearance, ultimately aiming to slow or delay disease progression. Preclinical studies have shown promising results, including reduced tau uptake and spread, as well as protective effects against behavioral deficits.
The ongoing Phase 2 TargetTau-1 trial is fully enrolled and incorporates various biomarkers of tau and amyloid-beta biology alongside clinical outcome measures to evaluate the efficacy of BMS-986446. Prothena stands to gain regulatory and sales milestone payments of up to $562.5 million from the collaboration, in addition to tiered royalties on net sales.
Prothena is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases and other conditions linked to protein dysregulation, with a pipeline that holds promise for addressing these challenging health issues.
MWN-AI** Analysis
Prothena Corporation plc (NASDAQ: PRTA) recently gained significant traction following Bristol Myers Squibb's (BMS) announcement that the U.S. FDA granted Fast Track Designation for BMS-986446, a promising anti-MTBR-tau antibody currently in Phase 2 trials for Alzheimer’s disease. This designation is a pivotal development in the drug's potential, indicating its role as a significant therapeutic option in an area of unmet medical need.
The Fast Track Designation expedites the review process of drugs intended to treat serious conditions, positioning BMS-986446 as a leading contender in the Alzheimer’s therapeutics market. Given the devastating nature of Alzheimer’s disease, with its profound impact on cognitive function and quality of life, the urgency for effective disease-modifying treatments cannot be overstated. With BMS-986446's unique mechanism targeting the microtubule binding region of tau protein, it may address the underlying pathology that contributes to neurodegeneration.
Investors should closely monitor the ongoing Phase 2 clinical trial, known as TargetTau-1, which aims to provide insights into both safety and efficacy. The incorporation of biomarkers for tau and amyloid-beta will be crucial for understanding the drug’s impact on disease progression. Encouraging preclinical results, coupled with the drug's safety profile observed in Phase 1 trials, support the hypothesis that BMS-986446 could significantly alter Alzheimer’s treatment paradigms.
Prothena stands to benefit substantially from this collaboration, with potential milestone payments exceeding $562.5 million and tiered royalties from net sales. These financial incentives could enhance Prothena's growth prospects, making it an attractive investment opportunity. As the market for Alzheimer's therapies evolves, Prothena's strategic positioning alongside BMS's development efforts could yield fruitful returns for investors willing to capitalize on the biotechnology sector's advancements.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
- Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease
Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease. Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.
Alzheimer’s disease — the most common type of dementia in adults — is a progressive, multifaceted and devastating neurodegenerative disease in which significant changes occur in the brain that cause neurons to die over time. These changes include the accumulation and spread of pathological tau, an abnormal form of the tau protein. Pathological tau protein fragments containing the microtubule binding region (MTBR) appear to have a key role in the underlying pathology of Alzheimer’s disease. By neutralizing the spread and promoting the clearance of pathological tau, BMS-986446 aims to modify the underlying course of the disease with the ultimate goal of slowing or delaying disease progression.
In preclinical models, BMS-986446 demonstrated significant reductions in tau uptake and spread, protection against behavioral deficits and was localized with tau pathology in Alzheimer’s brain tissue. BMS-986446 was also shown to be safe and well tolerated across three dose cohorts in a Phase 1 study of healthy participants. Bristol Myers Squibb also announced that the ongoing Phase 2 study is fully enrolled and includes several biomarkers of tau and amyloid-beta biology, as well as clinical outcome measures, to evaluate the impact of BMS-986446 on disease progression.
As part of the BMS-986446 global license with Bristol Myers Squibb, Prothena is eligible to receive additional regulatory and sales milestone payments of up to $562.5 million. Prothena also is eligible to receive tiered royalties on net sales. Bristol Myers Squibb is responsible for all communication, development, manufacturing, and commercialization for BMS-986446.
About BMS-986446 (PRX005)
BMS-986446 is a humanized monoclonal antibody that targets multiple domains of the microtubule binding region of tau, a highly pathogenic tau fragment associated with neurofibrillary tangle formation and cognitive decline in Alzheimer’s disease. BMS-986446 binds to specific regions of the tau protein (R1–R3 within the microtubule-binding domain) to prevent the cell-to-cell spread of tau and tau uptake into cells. It also activates microglia—the brain’s immune cells—through its Fc receptor function, promoting the clearance of tau via phagocytosis.
About the TargetTau-1 Phase 2 Trial ( NCT06268886 )
TargetTau-1 is a randomized, double-blind, placebo-controlled, global Phase 2 proof-of-concept study designed to evaluate the efficacy, safety and tolerability of multiple doses of BMS-986446 in participants with early Alzheimer’s disease. The study aims to determine whether targeting MTBR-tau can modify disease progression. In addition to clinical outcome measures, the trial integrates a comprehensive biomarker strategy to assess tau and amyloid-beta biology.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive, multifaceted and devastating neurodegenerative disease and the most common type of dementia in adults. Changes in the brain disrupt communication between neurons, impacting memory, cognition and behavior. As a result, Alzheimer’s disease has a significant impact on the day-to-day lives of those it directly affects, as well as on their families, caregivers and friends, resulting in considerable shifts in interpersonal relationships. There remains a critical need for disease-modifying therapies that can slow or delay the progression of Alzheimer’s disease as well as therapies that manage and ease neurobehavioral symptoms.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action BMS-986446; plans for ongoing clinical trials of BMS-986446; and amounts we might receive under our agreement with Bristol Myers Squibb. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2025, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251001695629/en/
Mark Johnson, CFA, Vice President, Investor Relations
650-837-8550
IR@prothena.com
Media@prothena.com
FAQ**
How does Prothena Corporation plc PRTA plan to leverage the Fast Track Designation granted to BMS-986446 in its strategic development and commercialization efforts for Alzheimer’s disease?
What specific clinical outcome measures and biomarker assessments are being utilized in the TargetTau-1 Phase 2 trial of BMS-986446 by Prothena Corporation plc PRTA?
Could you elaborate on the potential financial implications for Prothena Corporation plc PRTA regarding the milestone payments and royalties associated with BMS-986446's development and sales?
In what ways does Prothena Corporation plc PRTA plan to address the unmet medical needs of Alzheimer’s patients with the therapeutic mechanisms of action provided by anti-MTBR tau antibody?
**MWN-AI FAQ is based on asking OpenAI questions about Prothena Corporation plc (NASDAQ: PRTA).
NASDAQ: PRTA
PRTA Trading
-5.85% G/L:
$9.49 Last:
80,918 Volume:
$9.70 Open:
